Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: A Taiwanese Gynecologic Oncology Group study

• Published in: European journal of cancer (1990) Vol. 50; no. 18; pp. 3161 - 3167
• Main Authors: Chen, Chi-An, Lin, Hao, Weng, Chia-Sui, Wen, Kuo-Chang, Lu, Chien-Hsing, Chou, Hung-Hsueh, Huang, Yu-Fang, Kang, Chieh-Yi, Ho, Chih-Ming, Yu, Mu-Hsien, Chou, Cheng-Yang
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.12.2014; Elsevier
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; BEP regimen; Biological and medical sciences; Bleomycin - administration & dosage; Bleomycin - adverse effects; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Combined Modality Therapy; Etoposide - administration & dosage; Etoposide - adverse effects; Female; Fertility-sparing surgery; Hematology, Oncology and Palliative Medicine; Humans; Malignant germ cell tumours; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neoplasm Recurrence, Local - etiology; Neoplasms, Germ Cell and Embryonal - drug therapy; Neoplasms, Germ Cell and Embryonal - mortality; Neoplasms, Germ Cell and Embryonal - surgery; Organ Sparing Treatments; Outcome; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - surgery; Pharmacology. Drug treatments; Prognosis; Retrospective Studies; Treatment Outcome; Tumors; Young Adult; Asia; Taiwan; BEP regimen; Chemotherapy; Fertility-sparing surgery; Malignant germ cell tumours; Outcome; Antineoplastic agent; Prognosis; Peptides; Ovary cancer; Podophyllotoxin derivatives; Germ cell tumor; Isomerases; Bleomycin; Cancerology; Glycopeptide; Fertility; Surgery; Evolution; Antimitotic; Platinum II Complexes; Human; DNA topoisomerase (ATP-hydrolysing); Enzyme; Gynecology; Enzyme inhibitor; Etoposide; Topoisomerase II inhibitor; Malignant tumor; Cisplatin; Female genital diseases; Ovarian diseases; Alkylating agent; Antibiotic; Treatment; Therapeutic protocol; Cancer
• ISSN: 0959-8049; 1879-0852; 1879-0852
• DOI: 10.1016/j.ejca.2014.10.006

The combination of bleomycin, etoposide and cisplatin (BEP) is currently the most widely used treatment for malignant ovarian germ cell tumours (MOGCTs). The aim of this study was to evaluate the efficacy and adverse effects of the 3-day BEP regimen in Taiwan. The prognostic factors of the MOGCT patients were also analysed. Two hundred and thirty-nine cases of MOGCTs were identified from the Taiwanese Gynecologic Oncology Group database, and 204 of those who received postoperative BEP chemotherapy were then analysed. The estimated rate of no evidence of disease was 94.0% for 204 patients with adjuvant BEP regimen. Seven grade 3/4 haematological adverse effects including four subjects with neutropenia, one with pancytopenia and two with neutropenic fever were recorded in the 853 total courses of chemotherapeutic cycles. The rates of haematological and non-haematological adverse effects were 0.82% and 2.3%, respectively. No treatment-related mortality was noted. In the analysis of prognostic factors, only tumour stage had a significant impact on disease recurrence (95% confidence interval (CI), 4.2–94.4, p<0.001) and disease-related mortality (95% CI, 2.2–163.9, p=0.007). The current 3-day adjuvant BEP regimen was effective and safe for patients with MOGCTs.